Home » Feedback (FDBK) (Page 5)
Category Archives: Feedback (FDBK)
Can TexRAD CT measures of tumour heterogeneity stratify risk for nodal metastasis in patients with non-small cell lung cancer? – Feedback (FDBK)
Feedback (FDBK) – Can CT measures of tumour heterogeneity stratify risk for nodal metastasis in patients with non-small cell lung cancer? Source
Can CT measures of tumour heterogeneity stratify risk for nodal metastasis in patients with non-small cell lung cancer?.
Craigie M, et al. Clinical Radiology. 2017.
AIM: To undertake a preliminary assessment of the potential for computed tomography (CT) measurement of tumour heterogeneity to stratify risk of nodal metastasis in patients with non-small cell lung cancer (NSCLC).
MATERIALS & METHODS: Tumour heterogeneity in CT images from combined positron-emission tomography (PET)/CT examinations in 150 consecutive patients with NSCLC was assessed using CT texture analysis (CTTA). The short axis diameter of the largest mediastinal node was also measured. Forty-two patients without distant metastases subsequently had tumour nodal status confirmed at surgery (n=26) or endobronchial ultrasound (EBUS; n=16). CTTA parameters and largest nodal diameter were related to nodal status using the rank correlation and the risk ratio for each nodal stage (>N0, >N1, >N2) was compared between patients categorised as high and low risk by CTTA or nodal size. The most significant predictor of nodal status was related to overall survival using Kaplan-Meier analysis.
RESULTS: N-stage was more significantly correlated with CTTA than nodal diameter (Rs = -0.39, p=0.011, Rs = -0.45, p=0.0025, Rs = -0.40, p=0.0091 for normalised standard deviation (SD), normalised entropy and kurtosis respectively; Rs = -0.39, p=0.042 for nodal diameter). The presence of two or more high-risk CTTA values was the greatest risk factor for mediastinal metastasis (risk ratio: 11.0, 95% confidence interval: 1.56-77.8, p=0.0014) and was associated with significantly poorer overall survival (p=0.016).
CONCLUSION: CTTA in NSCLC is related to nodal status in patients without distant metastases and has the potential to inform selection of investigative strategies for the assessment of mediastinal malignancy.
Copyright © 2017 The Royal College of Radiologists. All rights reserved.
Original article link here
Feedback (FDBK) – Timothy Irish appointed as Non-Exec as Trevor Brown resigns.
Feedback plc (AIM: FDBK), the medical imaging software company, announces that Trevor Brown, has resigned as a Non-Executive Director of Feedback, with immediate effect, in order to allow the Company to move rapidly to the next stage in its development and to devote more time to his other business interests.
The Company is pleased to announce the appointment of Timothy Norris Irish as Non-Executive Director with immediate effect. Tim Irish is a Professor of Practice at Kings College London as well as a board member of Bournemouth University. Tim joined the board of the National Institute for Health and Care Excellence (NICE) in April 2015 and became the Senior Independent Director in May 2017. Tim has worked in the life sciences industry for thirty years. His career has spanned global health technology companies across Europe and North America, including GSK, GE and Philips the latter two in senior positions responsible for medical imaging. Tim also currently holds a number of non-executive positions in health and technology related entities.
Dr Alastair Riddell, Non-Executive Chairman, commented: “I should like to thank Trevor for his invaluable support of the Company following its readmission in 2014 which has enabled it to achieve substantial progress to date. We are delighted to announce the appointment of Tim Irish as a non-executive director. Tim’s experience and sector knowledge will strengthen the Board and assist the Company through its next significant growth phase.”
Trevor Brown, said: “It has been a pleasure to see Feedback develop over the last three years. The Company is about to embark on an exciting stage of its development and it is an appropriate time for me to step down to allow Alastair and the board scope to appoint directors with relevant industry experience and take the Company to the next level. I have indicated to the board that I am preparing to enter into an orderly market agreement in respect of my substantial shareholding, so as not to adversely affect the Company’s share price going forward.”
Tim Irish commented: “I am delighted to be joining the Board of Feedback at this exciting time in the Company’s development. I have been impressed with Feedback’s current technology offering, and I see great future potential for advanced imaging analytics to significantly improve patient outcomes.”
For further information contact:
|
Feedback plc |
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker) |
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
Regulatory Disclosures
In accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies, Timothy Norris Irish, aged 52 is, or has been within the last five years, a director or partner in the following companies and partnerships:
|
Current directorships and partnerships |
Past directorships and partnerships held within the last five years |
|
Quirem Medical BV |
FlexGen BV |
|
Fiagon AG |
Bmeye BV |
|
CfBT Schools Trust |
Mendor Oy |
|
Pembrokeshire Retreats Ltd |
Nexstim plc |
|
TTS Pharma Ltd |
|
|
Bioxydyn Limited |
|
|
Input Ideal Ltd |
|
|
Computabound Ltd |
|
|
Patech Solutions Ltd |
|
|
Deltex plc |
There is no other information required to be disclosed under the AIM Rules for Companies.
Feedback (FDBK) subsidiary Cambridge Computed Imaging announces exclusive distributor arrangement with Korea Computer Motion ISG
Feedback plc subsidiary Cambridge Computed Imaging Ltd (CCI) is pleased to announce the signing of an Exclusive Distributor arrangement with Korea Computer Motion ISG (Korea ISG) based in Seoul, South Korea for sales and distribution of its TexRAD® texture analysis research software. 
TexRAD will be used by customers for research purposes, performing advanced analysis of routinely acquired medical diagnostic images (e.g. CT, MRI) in South Korea.
As outlined in our recent investor presentations, this is a significant step for CCI Ltd as part of its plans to expand sales of TexRAD software to meet the fast-growing demand in Asian markets, identifying and engaging with distributors who are experts in the local market, and who can leverage the TexRAD brand awareness to help build a regional sales pipeline.
Dr Balaji Ganeshan, CEO of TexRAD Ltd and Director of New Business at Feedback Plc said; “We are pleased to sign this significant Distributorship agreement with Korea ISG to support the interest and acceptance of TexRAD in the rapidly growing and important South Korean medical imaging research market. We are confident that by working with an experienced team led by the CEO Jacob Woo, who has a great understanding of the market and customer base, we stand to increase the TexRAD revenue potential and market reach and meet our customer needs.”
Mr Jacob Woo, CEO of Korea ISG commented; “We are pleased to have started to work with CCI Ltd this year to promote the highly acclaimed TexRAD texture analysis software in South Korea which has attracted a lot of interest amongst the top University Hospitals who are also our potential-customers. Following a recent installation for research at the prestigious Korea University Hospital, I anticipate a very successful business relationship, rapidly increasing TexRAD software sales and working closely with Dr. Balaji Ganeshan and CCI. Our team has a first class reputation amongst researchers in the region, and offers unrivalled in-depth market-access and know-how in South Korea.”
About CCI
CCI Ltd is owned by AIM listed Feedback Plc (FDBK), based in Bourn, Cambridge UK. CCI focusses on the development and supply of advanced software including TexRAD, for texture analysis of medical images and storage and interpretation of imaging data.
About Korea Motion ISG
Korea ISG has installed and supported MRI/CT 3D processing imaging software to about 120 prominent Korean hospitals for 23 years, and is the largest medical imaging software distribution (sales and service/support) company in South Korea. They are experienced distributors of medical software from other world leading suppliers, with a wide customer base.
About TexRAD
TexRAD is a highly advanced, patented image texture analysis software tool that analyses routinely acquired diagnostic medical images (e.g. CT, MRI) to reveal features that are not always evident to the human eye. The platform also comprises a novel data-mining tool to assist the research customer to undertake statistical analysis to identify interesting parameters demonstrating association with patient outcome and clinical parameters. A number of research studies published in numerous peer-reviewed journals and conference presentations show that TexRAD texture metrics may have the potential to predict prognosis, disease severity and treatment prediction/evaluation in a number of cancer applications.
Contact for press enquiries
CCI Ltd: Mike Hayball, CEO Tel: 01954 718055
TexRAD Ltd: Dr. Balaji Ganeshan, CEO Tel: 01954 718072
Feedback plc: Alastair Riddell, Chairman Tel: 01954 718072
Brand Communications: Alan Green Tel: 07976 431608
Feedback (FDBK) – Total voting rights
Feedback announces that, as at today’s date, the Company’s issued share capital comprises 246,066,584 ordinary shares, with one voting right per share. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares and voting rights in the Company is 246,066,584.
The above figure may be used by shareholders in the Company as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules.
For further information, please contact:
|
Feedback plc |
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker) |
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
Feedback Plc (FDBK) – Further re. Resignation of Director Tom Charlton
Further to the announcement issued by the Company on 2 May 2017 regarding the resignation of Tom Charlton with effect from today, the Company announces that Tom Charlton has undertaken not to dispose of any shares in the Company registered in his name or in which he has a beneficial interest before the earlier of the date on which an orderly market agreement is entered into between Tom Charlton and the Company or 30 November 2017.
For further information contact:
|
Feedback plc |
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker) |
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
Proactive Investment Overview – Feedback PLC’s eye on the prize: a CE mark for TexRAD
The CE mark will enable Feedback to market not just to scientists, but radiologists everywhere, which should lead to a marked expansion in sales.
Dr Alastair Riddell’s CV reveals a high-flying career with the forerunners of what are now GE Healthcare, Johnson & Johnson and Pfizer, followed by spells guiding businesses to IPO or trade sale.
So, what attracted him to the challenge of Feedback plc (LON:FDBK), an AIM-listed medical imaging firm worth less than £9mln?
“The persistence of Tom Charlton, who would not give me any peace until I said yes,” jokes Riddell.
Charlton is one of Feedback’s major shareholders who recruited the Riddell as chairman.
However, Riddell’s mind was actually made up by cold hard data that underscored the potential of its main product, TexRAD.
“When I went to Cambridge and spoke to the people who do the work there it became clear there was real potential in this,” he told Proactive Investors.
“What really convinced me was a small study they’d done.”
Before we get to that study, it is worth getting a feel for TexRAD does.
It was the brainchild of the PhD of Dr Balaji Ganeshan, an expert on textural analysis of images gleaned from computed tomography (CT) scans.
Distilled down to the basics, it is essentially a very smart piece of software that analyses medical images, to reveal features that are not always evident to the human eye.
In doing so, it may “in a very statistical, objective and numerical way relate the output to a prognosis for the patient”, says Riddell.
Ganeshan carried out a study of patients with liver cancer using TexRAD and the results were, in the words of the Feedback chairman, “quite remarkable”.
“It quickly dawned on me that this could be a really valuable objective tool for giving an accurate prognosis,” he adds.
Riddell was announced as chairman in June 2016, and the focus has been on getting Feedback on to a commercial footing.
In April 2017 the company raised £750,000, issuing shares at 2.75p a pop, to invest in product development plus sales & marketing – mostly for TexRAD.
The fund-raising came in the wake of a breakthrough deal at the end of March that should see its TexRAD Lung product available on the diagnostic imaging platform of a leading global imaging company.
Feedback is already making money from TexRAD with sales to institutions carrying out research, but the promised land is filled with deals such as the TexRAD Lung partnership.
To fully commercialise the TexRAD product it must be granted a CE Mark, European certification for the technology.
It was on track to get this by the end of May 2017 but then it identified several new enhancements that will improve performance.
While that is good news, the discoveries mean that the award of the CE mark will be delayed “by several weeks”.
When it gets the thumbs-up from the EU, the mark will enable it to sell TexRAD to hospitals, where it will lend numerical support to the very skilled, interpretative work carried out by radiologists.
Meanwhile, a tie-up with a company in Poland called Future Processing provides Feedback with the coding know-how to develop a wider product suite.
Sales of the current product, though modest, reveal there is demand from a very specialist audience in the research sphere.
It means the technology is being cited in literature by some of the leading centres for cancer research – providing a great endorsement of the TexRAD from key opinion leaders.
In fact, the technology is also starting to make an impression with businesses operating in the field.
“My view is at the moment we are far too small and far too young to be engaged in corporate discussion,” says Riddell.
“But, if we can grow sales the way I hope we can grow them, then in two or three years we might look differently at these corporate approaches.”
In the meantime, it is about “investing in the company and doing things to a particular standard”, the Feedback chairman says.
“Of course, the next milestone will be getting the CE Mark for TexRAD,” he adds.
“This will enable us to market not just to scientists, but radiologists everywhere, which should lead to a marked expansion in sales.”
Read the full article on the Proactive Investors website here
Feedback (FDBK) – Progress with CE mark and trading update
Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to update shareholders on obtaining the CE Mark for TexRAD. The Group had previously announced its expectation of obtaining the CE mark for TexRAD Lung by a target date of end May 2017. In the course of development and review in compliance with ISO 13485:2016, enhancements have been identified which will improve the performance of this version of TexRAD and which will assist in the progression of future versions to wider clinical usage. The introduction of these modifications will result in a delay of several weeks before the CE Mark for TexRAD Lung is obtained. This is not expected to have any effect on the commercial negotiations which are underway or on future sales of TexRAD.
The CE mark will allow the sale of TexRAD Lung in the EU and certain other markets as a medical device that provides analysis of PET/CT images of lung cancer for clinical use. As previously announced, Feedback’s subsidiary company, Cambridge Computed Imaging Ltd, has signed a Letter of Intent with a leading global medical imaging company which would make TexRAD Lung available for purchase on its diagnostic imaging solutions platform. The schedule for release on this platform remains unaffected.
CCI continues to pursue its ongoing discussions with other leading imaging companies to broaden the range of potential routes to market for clinical versions of TexRAD. The funds raised from the recent placing have enabled the Company to initiate recruitment for business development and customer relations positions as well as scaling up the software development collaboration with Future Processing.
Note on CE Marking
CE marking is a claim by a medical device manufacturer that a product meets the essential requirements of relevant Medical Device Directives, which outline the safety and performance requirements for medical devices in the EU. CE marking (and compliance with the directives) is legally required before placing a device on the market in the EU. CCI has obtained certification to ISO 13485, the International Standard relating to quality management systems for organisations involved in the manufacture of medical devices. An appropriate quality management system and the preparation of a technical file are requirements for CE marking. The CE technical file is a comprehensive description of the device intended to demonstrate compliance with the Medical Device Directives and contains extensive documentation on the use, design, risk assessment, testing, clinical evaluation and manufacture of the device.
For further information contact:
|
Feedback plc |
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker) |
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Feedback (FDBK) – University of Sussex shareholding
|
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
|
|
1. Identity of the issuer or the underlying issuer |
|
||||
|
2 Reason for the notification (please tick the appropriate box or boxes): |
|||||
|
An acquisition or disposal of voting rights |
|||||
|
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|||||
|
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|||||
|
An event changing the breakdown of voting rights |
X |
||||
|
Other (please specify): |
|||||
|
3. Full name of person(s) subject to the |
University of Sussex |
||||
|
4. Full name of shareholder(s) |
As above |
||||
|
5. Date of the transaction and date on |
02/05/2017 |
||||
|
6. Date on which issuer notified: |
12/05/2017 |
||||
|
7. Threshold(s) that is/are crossed or |
4% |
||||
|
8. Notified details: |
|||||||||||||||
|
A: Voting rights attached to shares viii, ix |
|||||||||||||||
|
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
|||||||||||||
|
Number |
Number |
Number |
Number of voting |
% of voting rights x |
|||||||||||
|
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
|||||||||||
|
Ordinary Shares |
9,400,000 |
9,400,000 |
9,400,000 |
9,400,000 |
0 |
3.82% |
0 |
||||||||
|
B: Qualifying Financial Instruments |
|||||||||||||||
|
Resulting situation after the triggering transaction |
|||||||||||||||
|
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
|||||||||||
|
Ordinary Shares |
|||||||||||||||
|
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
|||||||||||||||
|
Resulting situation after the triggering transaction |
|||||||||||||||
|
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
||||||||||
|
Ordinary Shares |
|
Nominal |
Delta |
||||||||||||
|
Total (A+B+C) |
|||||||||||||||
|
Number of voting rights |
Percentage of voting rights |
||||||||||||||
|
9,400,000 |
3.82 |
||||||||||||||
|
9. Chain of controlled undertakings through which the voting rights and/or the |
||
|
|
||
|
Proxy Voting: |
||
|
10. Name of the proxy holder: |
||
|
11. Number of voting rights proxy holder will cease to hold: |
||
|
12. Date on which proxy holder will cease to hold voting rights: |
||
|
|
|
|
|
14. Contact name: |
Carey McLaughlin |
|
|
15. Contact telephone number: |
01273 678692 |
|
Brand CEO Alan Green talks Andalas Energy (ADL), Feedback (FDBK) & Vipera (VIP) on Vox Markets podcast
Brand CEO Alan Green talks Andalas Energy (ADL), Feedback (FDBK) & Vipera (VIP) with Justin Waite on the Vox Markets podcast. The interview is 42 minutes 15 seconds in.
Feedback (FDBK) – Notice of Resignation of Director
Feedback plc (AIM: FDBK), the medical imaging software company announces that Tom Charlton, non-executive Deputy Chairman of the Company, has given notice to the Board of Feedback that he intends to step down as a director on 30 May 2017 in order to devote more time to his other investment activities. Tom Charlton has indicated that he is prepared to enter into an orderly market agreement in respect of his substantial shareholding after he ceases to be a Director. The directors of the Company intend to appoint a further non-executive director with the appropriate skills to assist the Company in its next stage of development and a further announcement will be made in due course.
Dr. Alastair Riddell, non-executive Chairman, said, “I should like to thank Tom for his invaluable support of the Company following its readmission in 2014 which has enabled it to achieve remarkable progress to date. The recent placing now gives the Company the requisite capital to invest in building its commercial, regulatory and technical support capabilities to match the potential unlocked by the imminent CE mark and major collaborative distribution agreements. I look forward to the board being strengthened with the appointment of a further non-executive director to assist the Company through this significant growth phase.”
Tom Charlton said, “Having been the driving force behind Feedback’s move into medical imaging, I had always planned to step down as a Director after bringing in Alastair as an experienced Chairman to lead the Company to the next stage in its development. The future success of the Company is my key objective and therefore I am prepared to enter into an orderly market agreement regarding my shareholding to reassure shareholders.”
For further information contact:
|
Feedback plc |
Tel: 01954 718072 |
|
Allenby Capital Limited (Nominated Adviser and Joint Broker) |
Tel: 020 3328 5656 |
|
Northland Capital Partners Ltd (Joint Broker) |
Tel: 020 3861 6625 |
|
Peterhouse Corporate Finance Ltd (Joint Broker) |
Tel: 020 7469 0936 |
|
Brand Communications |
Tel: 07976 431608 |